CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, makers of excimer lasers and catheters for cardiovascular and dermatological diseases, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a broad patent (No. 9700655) that covers Ra Medical Systems’ DABRA™ catheter for cardiovascular disease treatment. The patent was granted […]
Coronary/Structural Heart
REVA Medical Cuts Jobs, Shakes Up C-Suite
SAN DIEGO, July 13, 2017 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA), as part of its transition to commercial operations, today announced the hiring of a new chief financial officer, a vice president of European sales, and the appointment of a new director to its board. These changes signal the […]
Testing a soft artificial heart
Press release by ETH, By: Franziska Schmid ETH researchers from the Functional Materials Laboratory have developed a silicone heart that beats almost like a human heart. In collaboration with colleagues from the Product Development Group Zurich, they have tested how well it works. The artificial heart imitates a human heart as closely […]
Medtronic Expands TAVR Access to More Patients With Symptomatic, Severe Aortic Stenosis Upon Intermediate Risk FDA Approval
Press Release DUBLIN – July 10, 2017 – Medtronic plc (NYSE: MDT) today announced the expanded U.S. Food and Drug Administration (FDA) approval of the self-expanding CoreValve(TM) Evolut(TM) transcatheter aortic valve replacement (TAVR) platform to include patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-heart surgery. […]
Andrew ElBardissi, M.D. Named to NeoChord Board of Directors
ST. LOUIS PARK, Minn., July 10, 2017 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of minimally invasive valve repair for degenerative mitral regurgitation (DMR), today announced the appointment of Andrew ElBardissi, M.D. to its Board of Directors, effective immediately. Dr. ElBardissi is replacing Avi Kometz, […]
Innovative Cardiovascular Solutions Raises $5.0 Million in Series B Financing for Advanced Device Development and Initiation of U.S. Clinical Activities
KALAMAZOO, Mich., July 11, 2017 /PRNewswire/ — Innovative Cardiovascular Solutions, LLC (ICS), a privately-held clinical stage company headquartered in Kalamazoo, MI, announced today completion of an oversubscribed Series B round of financing totaling $5M USD. The company is currently developing the EMBLOK™ Embolic Protection System which is designed for use in Transcatheter Aortic Valve Replacement […]
RA Medical Names Maurice Buchbinder, M.D., And Martin Colombatto To Board Of Directors
CARLSBAD, Calif.–(BUSINESS WIRE)–Following the €1.9 billion ($2.16 billion) purchase of The Spectranetics Corporation (NASDAQ:SPNC) by Royal Philips (NYSE:PHG), Ra Medical Systems, makers of cardiovascular and dermatology catheters and excimer lasers, today announced the appointment of two new members to the Company’s Board of Directors. This also follows the recent FDA market […]
Stent coated with Viagra may help prevent blood clots
Stent coated with Viagra may help prevent blood clots By AMERICAN HEART ASSOCIATION NEWS Coating heart stents with the erectile dysfunction drug Viagra, known by the generic name sildenafil, could one day reduce blood clots and re-narrowing of arteries, according to new research. Stents prop open heart arteries to help […]
Medtronic Expands TAVR Access to More Patients With Symptomatic, Severe Aortic Stenosis Upon Intermediate Risk FDA Approval
DUBLIN – July 10, 2017 – Medtronic plc (NYSE: MDT) today announced the expanded U.S. Food and Drug Administration (FDA) approval of the self-expanding CoreValve(TM) Evolut(TM) transcatheter aortic valve replacement (TAVR) platform to include patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-heart surgery. With hemodynamic […]
Resverlogix (RVX.TO) Randomizes First Patient In Taiwan/China Portion Of The Phase III BETonMACE Clinical Trial
CALGARY, July 10, 2017 /PRNewswire/ – Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) today announced that the first patient has been randomized in Taiwan in the Phase 3 BETonMACE clinical trial with lead drug apabetalone intended for high-risk patients with cardiovascular disease (“CVD”) and type 2 diabetes mellitus (“DM”). On July 8, 2015, Resverlogix and […]



